From Jakarta to Surabaya: China–Indonesia Collaboration in Cancer Care Gains Momentum as GCCC Radiotherapy Program Draws Strong Interest
From August 14 to 16, 2026, Guangzhou Concord Cancer Center (GCCC) carried out a series of overseas exchange activities in Jakarta and Surabaya, Indonesia — including a cancer health talk and the Surabaya International Health and Medical Expo — marking another important step in deepening international medical cooperation and promoting the international exchange of quality medical resources.
Indonesia is the most populous country in Southeast Asia and one of the world's major source markets for medical tourism. In recent years, with the rising incidence of cancer and the growing demand for high-quality medical services, a large number of Indonesian patients have chosen to seek medical treatment overseas, which fully reflects the urgent need of local patients for advanced international oncology services.
GCCC's visit to Indonesia aims to address this demand by bringing internationally standardized oncology diagnosis and treatment services closer to Indonesian patients. The trip combined a public health talk, exhibition participation, and on-site patient consultations to introduce advanced radiotherapy and proton therapy expertise to local clinicians, patients, and partners.
Jakarta Cancer Health Talk: 100+ Attendees Explore Modern Radiotherapy
On the evening of August 14, 2026, Qian Chaonan, President of GCCC, and Ms. Zhou Minping, Director of Nursing, attended a cancer health talk in Jakarta with around 100 attendees. President Qian delivered a presentation titled "Radiation Therapy in Modern Oncology: Principles, Modalities, and Clinical", showcasing the hospital's professional expertise and advanced technologies in oncology diagnosis and treatment — leaving a deep impression on the audience.
After the talk, representatives from local medical institutions expressed interest in collaboration, while many patients and their families made detailed inquiries about seeking medical treatment in China. The response was enthusiastic.
Radiation therapy is one of the most powerful tools in modern oncology. Our goal in sharing this knowledge is to help Indonesian patients better understand their options and to make advanced cancer care more accessible. Qian Chaonan, President of Guangzhou Concord Cancer Center
Surabaya International Health and Medical Expo: Three Days, 50+ Patient Consultations
From August 14 to 16, 2026, the GCCC team attended the Surabaya International Health and Medical Expo (IMWTE 2026). President Qian Chaonan, Ms. Zhou Minping, Deputy Director of Nursing, and You Jin, Head of International Medical Services, were on site, receiving nearly 50 patient consultations over the three days.
President Qian also delivered a hospital-specific radiotherapy lecture titled "Radiation Therapy in Modern Oncology: Principles, Modalities, and Clinical", and participated in a panel discussion with local counterparts to explore cancer treatment, drawing an enthusiastic response.
GCCC's Advanced Radiotherapy Capability: 1,000+ Patients in 19 Months
As the first operational proton therapy center in South China (excluding Hong Kong and Macau), GCCC has established a long-term partnership with MD Anderson Cancer Center and provides cancer care services in accordance with international standards. The hospital's Proton Therapy Center, which officially commenced clinical operations in December 2024, is the first operational proton therapy center in South China (excluding Hong Kong and Macau).
Since its clinical launch, the center has provided proton radiotherapy to over 1,000 patients within 19 months, with consecutive single-day treatment volumes exceeding 100 patients, placing its operational efficiency among the top tier internationally.
Proton therapy has broad clinical applicability, covering dozens of solid tumor types including head and neck tumors, intracranial tumors, lung cancer, breast cancer, digestive system tumors, urinary system tumors, gynecological tumors, ocular tumors, bone and soft tissue sarcomas, and lymphomas. Patients range in age from 13 months to 91 years, achieving full age-spectrum coverage, with over 120 pediatric patients under the age of 14. The patient base spans 32 provincial-level administrative regions across China and has also benefited international patients from more than 20 countries, including those from Europe, the Americas, and Southeast Asia.
Clinical scope: Proton therapy at GCCC covers head and neck tumors, intracranial tumors, lung cancer, breast cancer, digestive system tumors, urinary system tumors, gynecological tumors, ocular tumors, bone and soft tissue sarcomas, lymphomas, and more — suitable for both adult and pediatric patients.
International-Standard Cancer Care: A Long-Term Partnership with MD Anderson
GCCC's cancer care services are delivered in accordance with international standards, supported by a long-term partnership with MD Anderson Cancer Center. This collaboration spans clinical practice, multidisciplinary consultation, quality control, and academic exchange, helping ensure that patients at GCCC receive care aligned with leading international protocols.
Toward a "Healthy Silk Road": Future Cooperation with Indonesia
GCCC stated that the demand for high-quality oncology services among Indonesian patients is growing, and the hospital is willing to work hand in hand with local medical institutions and social organizations to jointly improve cancer prevention and treatment, benefiting more patients.
The hospital will take this series of activities as an opportunity to expand cooperation with medical institutions and social organizations in Indonesia, promoting the establishment of regularized collaboration mechanisms — thereby contributing to the building of a "Healthy Silk Road."
- Oncology diagnosis and treatment: Joint clinical pathways and quality standards for cancer care.
- Patient referrals: Streamlined referral processes for Indonesian patients seeking treatment in China.
- Talent development: Training programs and academic exchange for Indonesian clinicians and nurses.
- Technology sharing: Sharing of advanced radiotherapy, proton therapy, and digital healthcare expertise.
- Public education: Continued health talks and awareness events for Indonesian communities.
About GCCC: Guangzhou Concord Cancer Center is a comprehensive cancer care institution specializing in advanced oncology treatment, precision radiotherapy, multidisciplinary cancer management, and innovative healthcare solutions. As the first operational proton therapy center in South China (excluding Hong Kong and Macau), GCCC is committed to providing international-standard cancer care and to building long-term partnerships that improve patient access to high-quality oncology services across borders.
Frequently Asked Questions
From August 14 to 16, 2026, Guangzhou Concord Cancer Center conducted a cancer health talk in Jakarta and participated in the Surabaya International Health and Medical Expo (IMWTE 2026), receiving nearly 50 patient consultations over the three days.
President Qian Chaonan delivered a presentation titled "Radiation Therapy in Modern Oncology: Principles, Modalities, and Clinical", introducing the principles of radiotherapy, the main modalities, and clinical applications in modern cancer treatment.
Since its clinical launch in December 2024, GCCC's Proton Therapy Center has treated more than 1,000 patients within 19 months, with consecutive single-day treatment volumes exceeding 100 patients — placing its operational efficiency among the top tier internationally.
The proton therapy center serves patients from 32 provincial-level administrative regions across China and has also benefited international patients from more than 20 countries, including those from Europe, the Americas, and Southeast Asia.
GCCC will expand cooperation with medical institutions and social organizations in Indonesia, promoting regularized collaboration mechanisms in areas such as oncology diagnosis and treatment, patient referrals, talent development, and technology sharing — contributing to the building of a "Healthy Silk Road."